Cargando…
Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway
BACKGROUND: Osteolytic diseases such as osteoporosis are featured with accelerated osteoclast differentiation and strong bone resorption. Considering the complications and other limitations of current drug treatments, it is necessary to develop a safer and more reliable drug to deal with osteoclast-...
Autores principales: | Wu, Xinhui, Zhao, Kangxian, Fang, Xiaoxin, Lu, Feng, Zhang, Weikang, Song, Xiaoting, Chen, Lihua, Sun, Jiacheng, Chen, Haixiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627275/ https://www.ncbi.nlm.nih.gov/pubmed/34848946 http://dx.doi.org/10.2147/DDDT.S334421 |
Ejemplares similares
-
Saikosaponin D Inhibited IL-1β Induced ATDC 5 Chondrocytes Apoptosis In Vitro and Delayed Articular Cartilage Degeneration in OA Model Mice In Vivo
por: Wu, Xinhui, et al.
Publicado: (2022) -
Magnesium Lithospermate B Protects against Lipopolysaccharide-Induced Bone Loss by Inhibiting RANKL/RANK Pathway
por: Wang, Jihai, et al.
Publicado: (2018) -
Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo
por: Peng, Jiaxuan, et al.
Publicado: (2020) -
RANKL/RANK: from bone loss to the prevention of breast cancer
por: Sigl, Verena, et al.
Publicado: (2016) -
RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)